Johnson & Johnson
NYSE:JNJ
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
142.2123
167.38
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Johnson & Johnson
Johnson & Johnson
Revenue
Johnson & Johnson
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$87.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$47.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$60.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$63.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Revenue
$9.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$40.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
Johnson & Johnson
Revenue Breakdown
Breakdown by Geography
Johnson & Johnson
|
Total Revenue:
85.2B
USD
|
|
United States Plans:
46.4B
USD
|
|
Non-Us:
38.7B
USD
|
Breakdown by Segments
Johnson & Johnson
|
Total Revenue:
85.2B
USD
|
|
Innovative Medicine:
54.8B
USD
|
|
Medtech:
30.4B
USD
|
|
Stelara:
10.9B
USD
|
|
Darzalex:
9.7B
USD
|
|
General:
5.4B
USD
|
|
Electrophysiology:
4.7B
USD
|
|
Advanced:
4.7B
USD
|
|
Invega Sustenna/Xeplion/Trinza/Trevicta:
4.1B
USD
|
|
Contact Lenses/Other:
3.7B
USD
|
|
Imbruvica:
3.3B
USD
|
|
Tremfya:
3.1B
USD
|
|
Trauma:
3B
USD
|
|
Spine,Sports & Other:
2.9B
USD
|
|
Erleada:
2.4B
USD
|
|
Xarelto:
2.4B
USD
|
|
Simponi/Simponi Aria:
2.2B
USD
|
|
Opsumit:
2B
USD
|
|
Prezista/Prezcobix/Rezolsta/Symtuza:
1.9B
USD
|
|
Remicade:
1.8B
USD
|
|
Uptravi:
1.6B
USD
|
|
Hips:
1.6B
USD
|
|
Other Neuroscience:
1.6B
USD
|
|
Knees:
1.5B
USD
|
|
Surgical:
1.4B
USD
|
|
Abiomed:
1.3B
USD
|
|
Other:
1.3B
USD
|
|
Edurant/Rilpivirine:
1.2B
USD
|
|
Covid-19:
1.1B
USD
|
|
Zytiga/Abiraterone Acetate:
887m
USD
|
|
Other Oncology:
879m
USD
|
|
Concerta/Methylphenidate:
783m
USD
|
|
Risperdal Consta:
689m
USD
|
|
Carvykti:
500m
USD
|
|
Other Interventional Solutions:
356m
USD
|
|
Other Infectious Diseases:
297m
USD
|
|
Other Immunology:
11m
USD
|
Johnson & Johnson
Glance View
Founded in 1886, Johnson & Johnson began its journey with a commitment to revolutionizing healthcare, starting with the sterile surgical dressings it produced to reduce infections in hospitals. Over the decades, this vision expanded into a global healthcare powerhouse, intricate in its operation yet unified in its mission to improve lives. Johnson & Johnson's business model is built on three core segments: pharmaceuticals, medical devices, and consumer health products. Each segment harnesses the synergy of innovation, research, and a deep understanding of customer needs. The pharmaceutical division, one of its most robust, thrives on producing treatments for various medical conditions, including immunology, oncology, and neuroscience. It is in this domain that cutting-edge research and development efforts translate into high-margin therapies, driving substantial portions of the company's revenue. Beyond pharmaceuticals, the medical devices segment forms a pillar of Johnson & Johnson's operations, offering a spectrum of products essential for surgeries, orthopedics, and vision care. These devices are integral for modern healthcare practices, with their premium positioning contributing significantly to the company’s financial health. Meanwhile, Johnson & Johnson's consumer health division addresses everyday wellness needs, with iconic brands like Band-Aid, Tylenol, and Neutrogena. This segment leverages global brand recognition and trust to generate steady, albeit lower-margin, income streams. Together, these segments compose a diversified revenue platform, buffered against sector-specific downturns and positioning Johnson & Johnson as a formidable entity in global healthcare markets.
See Also
What is Johnson & Johnson's Revenue?
Revenue
87.7B
USD
Based on the financial report for Sep 29, 2024, Johnson & Johnson's Revenue amounts to 87.7B USD.
What is Johnson & Johnson's Revenue growth rate?
Revenue CAGR 10Y
2%
Over the last year, the Revenue growth was 5%. The average annual Revenue growth rates for Johnson & Johnson have been -1% over the past three years , 1% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
